Markerless motion capture for the clinical assessment of human movement

描述（由申请人提供）：本项目的总体目标是将无标记运动捕捉系统产品化和商业化，用于生物力学和临床实践。与传统上使用的基于标记的系统相反，无标记系统将为生物力学和临床实践中的应用提供简单、成本有效、有效和准确的人体运动的3D测量。第二阶段项目的具体重点是使第二阶段验证的原型成为一个强大的产品，并将其商业化用于步态分析和运动医学应用。 公共卫生相关性：本申请提出了一种商业产品的开发，包括一个无标记的运动捕捉系统，将改变人类运动的临床评估的方式实现。这笔赠款将使这项技术在研究和临床实践中的开发和商业化得以完成。在第一阶段，Mixamo和斯坦福大学成功地合作实现了原型并在临床设置中进行了验证。这两个机构拥有人体运动分析领域最前沿的研究人员作为其团队成员。动作捕捉是Mixamo，Inc.核心业务和斯坦福大学生物运动实验室是无标记技术诞生的地方。Mixamo的创始人兼首席执行官Stefano Corazza一直在斯坦福大学生物运动实验室从事这项技术的早期研究，他是一名私家侦探。目前的补助金。在第二阶段的应用中，Mixamo率先将产品推向市场并将其商业化。该技术已经走过了漫长的道路，并准备在临床步态分析和生物力学市场产生革命性的影响。

DESCRIPTION (provided by applicant): The overall objective of this project is to productize and commercialize a markerless motion capture system for applications in biomechanical and clinical practice. The markerless system, as opposed to traditionally used marker based systems, would provide simple, cost effective, efficient and accurate 3D measurements of human movement for applications in biomechanical and clinical practice. The specific focus of this Phase II project is to make the prototype validated in Phase II a robust product and to commercialize it for gait analysis and sport medicine applications. PUBLIC HEALTH RELEVANCE: This application proposes the development of a commercial product consisting of a markerless motion capture system that will change the way clinical assessment of human motion is achieved. The grant will enable the completion of the developments and the commercialization of this technology in research and in clinical practices. In Phase I Mixamo and Stanford University have collaborated successfully in the realization of a prototype and its validation in a clinical setup. The two institutions have the most cutting edge researchers in the human motion analysis field as members of their teams. Motion capture is one of Mixamo, Inc's. core businesses and the Stanford Biomotion Lab is where the markerless technology was born. The founding CEO of Mixamo, Stefano Corazza, has been working on the early stagees of the technology at the Stanford Biomotion Lab and he is P.I. of the present grant. In this Phase II application Mixamo is taking the lead in making a product ready for the market and commercializing it. The technology has come a long way and is ready for a revolutionary impact in the market of clinical gait analysis and biomechanics.